Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > We may see

<< Previous

Bullboard Posts

Next >>

Comment by JohnnyYegon Jun 04, 2021 3:00pm

229 Views

Post# 33331290

RE:RE:We may see

The Poster announced on May 20 PR was made available today at the 2021 ASCO Annual Meeting. Unfortunately, unless I'm missing something, you have to be a paid "attendee" to view it. Apparently it is good, but pretty much reiterating what was presented in abstract overview in the PR.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec